A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study of an Anti-IL-13 Monoclonal Antibody in Healthy Subjects and Mild Asthmatics
British Journal of Clinical Pharmacology, 05/25/2012Hodsman GP et al.
GSK679586 demonstrated dose–dependent pharmacological activity in the lungs of mild intermittent asthmatics. These findings, together with the favorable safety profile and advantageous PK characteristics of a monoclonal antibody (e.g. a long half–life supporting less frequent dosing), warrant further investigation of GSK679586 in a broader asthma patient population.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.